2022
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
Geyer C, Sikov W, Huober J, Rugo H, Wolmark N, O’Shaughnessy J, Maag D, Untch M, Golshan M, Lorenzo J, Metzger O, Dunbar M, Symmans W, Rastogi P, Sohn J, Young R, Wright G, Harkness C, McIntyre K, Yardley D, Loibl S. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Annals Of Oncology 2022, 33: 384-394. PMID: 35093516, DOI: 10.1016/j.annonc.2022.01.009.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerEvent-free survivalAddition of carboplatinNeoadjuvant chemotherapyOverall survivalHazard ratioBreast cancerEarly-stage triple-negative breast cancerPathological complete response rateRandomized phase III trialComplete response rateCyclophosphamide neoadjuvant chemotherapyManageable acute toxicitiesManageable safety profileSafety of additionUntreated stage IIStandard neoadjuvant chemotherapyPhase III trialsCo-primary endpointsLong-term efficacyAcute myeloid leukemiaWeekly paclitaxelPrimary endpointSecondary endpointsIII trials
2021
ASO Author Reflections: Apocrine Breast Cancer: More Questions than Answers
Saridakis A, Berger ER, Greenup R, Golshan M, Lannin DR. ASO Author Reflections: Apocrine Breast Cancer: More Questions than Answers. Annals Of Surgical Oncology 2021, 29: 581-582. PMID: 34743280, DOI: 10.1245/s10434-021-10649-z.Peer-Reviewed Original ResearchExploring the impact of exercise and mind–body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgery
Knoerl R, Giobbie-Hurder A, Sannes TS, Chagpar AB, Dillon D, Dominici LS, Frank ES, Golshan M, McTiernan A, Rhei E, Tolaney SM, Winer EP, Yung RL, Irwin ML, Ligibel JA. Exploring the impact of exercise and mind–body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgery. Supportive Care In Cancer 2021, 30: 2027-2036. PMID: 34648061, DOI: 10.1007/s00520-021-06617-8.Peer-Reviewed Original ResearchConceptsCancer treatment-related symptomsPrehabilitation interventionsTreatment-related symptomsTime of enrollmentImpact of exerciseQuality of lifeBreast cancerGroup participantsPre-operative exerciseBreast cancer surgeryMind-body interventionsCognitive functioningOpportunity trialCancer surgeryOutcome measuresSecondary analysisOne monthSurgeryMeasures of qualityGroup comparisonsCancer diagnosisCancerWomenInterventionSignificant differencesSurgical Management of Hereditary Breast Cancer
Berger ER, Golshan M. Surgical Management of Hereditary Breast Cancer. Genes 2021, 12: 1371. PMID: 34573353, PMCID: PMC8470490, DOI: 10.3390/genes12091371.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsChemopreventionFemaleGenetic Predisposition to DiseaseGenetic TestingHereditary Breast and Ovarian Cancer SyndromeHeterozygoteHumansMastectomyMutationPractice Guidelines as TopicProphylactic Surgical ProceduresSalpingo-oophorectomyConceptsHereditary breast cancerBreast cancerGenetic variant carriersSurgical risk reductionSurgical management optionsSurgical managementBreast/ovarian cancer susceptibility geneOvarian cancer susceptibility genesVariant carriersCancer susceptibility genesGenetic testingCancer treatmentCancerRisk reductionSusceptibility genesManagement optionsApocrine Breast Cancer: Unique Features of a Predominantly Triple-Negative Breast Cancer
Saridakis A, Berger ER, Harigopal M, Park T, Horowitz N, Le Blanc J, Zanieski G, Chagpar A, Greenup R, Golshan M, Lannin DR. Apocrine Breast Cancer: Unique Features of a Predominantly Triple-Negative Breast Cancer. Annals Of Surgical Oncology 2021, 28: 5610-5616. PMID: 34426884, DOI: 10.1245/s10434-021-10518-9.Peer-Reviewed Original ResearchConceptsBreast cancer-specific survivalCancer-specific survivalHigh-grade tumorsMolecular subtypesApocrine carcinomaBreast cancerBetter survivalHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Triple-negative breast cancerRare breast cancerEnd Results (SEER) databaseGrowth factor receptor 2Triple-negative patientsTriple-negative cancersLow-grade tumorsFactor receptor 2Life table methodApocrine tumorsLuminal patientsWorse survivalClinicopathologic featuresResults databaseAggressive featuresReceptor 2Cancer Awareness and Stigma in Rural Assam India: Baseline Survey of the Detect Early and Save Her/Him (DESH) Program
Pak LM, Purad CC, Nadipally S, Rao MP, Mukherjee S, Hegde SKB, Golshan M. Cancer Awareness and Stigma in Rural Assam India: Baseline Survey of the Detect Early and Save Her/Him (DESH) Program. Annals Of Surgical Oncology 2021, 28: 7006-7013. PMID: 34215953, DOI: 10.1245/s10434-021-10366-7.Peer-Reviewed Original ResearchConceptsCancer screening programsScreening programCervical cancerBaseline surveyAcceptance of screeningRural Indian populationMobile screening programLong-term detrimental effectsOne-thirdOral ulcersPreventable causeCancer awarenessCancer knowledgeCancer patientsCancer symptomsActionable targetsMedical careCancerCancer educationCancer etiologyBetel nutConclusionsThis studyIndian populationCarcinogenic effectsCancer diagnosisOptimal Management for Residual Disease Following Neoadjuvant Systemic Therapy
Foldi J, Rozenblit M, Park TS, Knowlton CA, Golshan M, Moran M, Pusztai L. Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy. Current Treatment Options In Oncology 2021, 22: 79. PMID: 34213636, DOI: 10.1007/s11864-021-00879-4.Peer-Reviewed Original ResearchConceptsPathologic complete responseResidual cancerClinical trialsAdjuvant therapyExcellent long-term disease-free survivalLong-term disease-free survivalAxillary lymph node dissectionHuman epidermal growth factor receptor 2Early-stage breast cancerEpidermal growth factor receptor 2Post-mastectomy breastSystemic adjuvant therapyInternal mammary nodesLymph node dissectionNeoadjuvant systemic therapyDisease-free survivalGrowth factor receptor 2Minimal residual disease monitoringRecurrence-free survivalType of surgeryPivotal clinical trialsOngoing clinical trialsFactor receptor 2Residual disease monitoringAccurate prognostic estimatesASO Author Reflections: Accurately Predicting Nodal pCR Holds the Key to Axillary Surgery De-escalation Strategies
Weiss A, Golshan M, Ollila DW. ASO Author Reflections: Accurately Predicting Nodal pCR Holds the Key to Axillary Surgery De-escalation Strategies. Annals Of Surgical Oncology 2021, 28: 5972-5973. PMID: 33851312, DOI: 10.1245/s10434-021-09953-5.Peer-Reviewed Original ResearchFactors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance)
Weiss A, Campbell J, Ballman KV, Sikov WM, Carey LA, Hwang ES, Poppe MM, Partridge AH, Ollila DW, Golshan M. Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). Annals Of Surgical Oncology 2021, 28: 5960-5971. PMID: 33821344, PMCID: PMC8532250, DOI: 10.1245/s10434-021-09897-w.Peer-Reviewed Original ResearchConceptsBreast pathologic complete responsePathologic complete responseResidual breast diseaseTriple-negative breast cancerNodal pathologic complete responsePretreatment nodal statusClinical nodal statusNeoadjuvant chemotherapyNodal statusAxillary surgeryComplete responseCALGB 40601YpN0 rateAxillary nodal involvementResidual nodal diseaseProportion of patientsCareful patient selectionBreast cancer patientsNAC regimensYpN0 diseaseYpN0 statusCN0 patientsNodal diseaseNodal involvementMultivariable analysisAssociation of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
Filho OM, Stover DG, Asad S, Ansell PJ, Watson M, Loibl S, Geyer CE, Bae J, Collier K, Cherian M, O’Shaughnessy J, Untch M, Rugo HS, Huober JB, Golshan M, Sikov WM, von Minckwitz G, Rastogi P, Maag D, Wolmark N, Denkert C, Symmans WF. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. JAMA Oncology 2021, 7: 603-608. PMID: 33599688, PMCID: PMC7893540, DOI: 10.1001/jamaoncol.2020.7310.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerPathologic complete responseNeoadjuvant chemotherapyGene expression-based molecular subtypesComplete responseMolecular subtypesBreast cancerClinical trialsSecondary analysisStage IIEnd pointAddition of carboplatinClinical stage IIDe-escalate therapyHigh pCR ratePrespecified end pointPrespecified secondary analysisSecondary end pointsStandard neoadjuvant chemotherapySimilar baseline characteristicsSubset of patientsT cell infiltrationRandomized clinical trialsTumor cell proliferationWhole transcriptome RNA sequencingPrediction of Persistent Pain Severity and Impact 12 Months After Breast Surgery Using Comprehensive Preoperative Assessment of Biopsychosocial Pain Modulators
Schreiber KL, Zinboonyahgoon N, Flowers KM, Hruschak V, Fields KG, Patton ME, Schwartz E, Azizoddin D, Soens M, King T, Partridge A, Pusic A, Golshan M, Edwards RR. Prediction of Persistent Pain Severity and Impact 12 Months After Breast Surgery Using Comprehensive Preoperative Assessment of Biopsychosocial Pain Modulators. Annals Of Surgical Oncology 2021, 28: 5015-5038. PMID: 33452600, PMCID: PMC8280248, DOI: 10.1245/s10434-020-09479-2.Peer-Reviewed Original ResearchConceptsBody mass indexPain severitySensory disturbanceBreast surgeryProspective longitudinal observational cohort studyLongitudinal observational cohort studyHigher body mass indexComprehensive preoperative assessmentFirst postsurgical yearPost-mastectomy painObservational cohort studyBaseline sleep disturbanceFunctional impactPostsurgical yearAxillary dissectionPain modulatorsPreoperative characteristicsWorst painCohort studyPain outcomesPain processingPain QuestionnaireSurgical variablesMass indexPain impact
2020
Omission of Surgical Axillary Lymph Node Staging in Patients with Tubular Breast Cancer
Özkurt E, Wong S, Rhei E, Golshan M, Brock J, Barbie TU. Omission of Surgical Axillary Lymph Node Staging in Patients with Tubular Breast Cancer. Annals Of Surgical Oncology 2020, 28: 2589-2598. PMID: 33078312, DOI: 10.1245/s10434-020-09223-w.Peer-Reviewed Original ResearchConceptsInvasive ductal carcinomaER-positive invasive ductal carcinomasSurgical axillary stagingNational Cancer DatabaseTubular carcinomaLN involvementAxillary stagingOverall survivalDuctal carcinomaGrade IBreast cancerPositive invasive ductal carcinomaAxillary lymph node stagingKaplan-Meier survival curvesAxillary LN involvementFavorable breast cancerLN-positive diseasePropensity-matched analysisKaplan-Meier methodLymph node metastasisLymph node stagingTubular breast cancerLN diseaseNCDB cohortNodal involvement
2016
Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity?
Criscitiello C, Curigliano G, Burstein H, Wong S, Esposito A, Viale G, Giuliano M, Veronesi U, Santangelo M, Golshan M. Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity? European Journal Of Surgical Oncology 2016, 42: 1780-1786. PMID: 27825710, DOI: 10.1016/j.ejso.2016.10.011.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsAxillaBreast NeoplasmsClinical Decision-MakingFemaleGenes, BRCA1Genes, BRCA2Genetic Predisposition to DiseaseHereditary Breast and Ovarian Cancer SyndromeHumansLymph Node ExcisionMastectomyMastectomy, SegmentalMedical OveruseNeoadjuvant TherapyPatient PreferenceSurgical OncologyConceptsBreast conservationNeoadjuvant therapyBreast cancerSystemic therapyPathologic complete response rateComplete response rateBreast conservation ratesEffective systemic treatmentPatient-level variablesInvasive surgical approachNeoadjuvant trialsInoperable patientsSurgical overtreatmentSystemic treatmentSurgical approachSurgical benefitsOncology communityResponse ratePatientsTherapyCancerAggressive optionsMastectomySurgeonsConservation rate
2015
Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do?
Criscitiello C, Giuliano M, Curigliano G, De Laurentiis M, Arpino G, Carlomagno N, De Placido S, Golshan M, Santangelo M. Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do? European Journal Of Surgical Oncology 2015, 41: 1288-1292. PMID: 26238477, DOI: 10.1016/j.ejso.2015.07.013.Peer-Reviewed Original ResearchConceptsDe novo metastatic breast cancerNovo metastatic breast cancerMetastatic breast cancerBreast cancer patientsBreast cancerSurvival benefitCancer patientsPrimary tumorRetrospective non-randomized clinical studyDe novo metastatic diseasePrimary metastatic breast cancerNon-randomized clinical studyTumor-related symptomsPrimary tumor excisionSelection of patientsWound issuesBiologic therapyMetastatic diseaseSystemic therapyDistant metastasisEpidemiological burdenInitial diagnosisSurgical excisionPatient preferencesTumor excisionBilateral Synchronous Benign Phyllodes Tumors
Mallory MA, Golshan M, Chikarmane S, Raza S, Lester S, Caterson S. Bilateral Synchronous Benign Phyllodes Tumors. The American Surgeon 2015, 81: 192-194. PMID: 25975306, PMCID: PMC4477195, DOI: 10.1177/000313481508100503.Peer-Reviewed Original Research
2010
Can axillary lymph node dissection be omitted in patients with breast cancer and positive sentinel nodes?
Dominici L, Golshan M. Can axillary lymph node dissection be omitted in patients with breast cancer and positive sentinel nodes? Minerva Surgery 2010, 65: 547-54. PMID: 21081866.Peer-Reviewed Original ResearchConceptsBreast cancerSentinel lymphAxillary lymph node dissectionPositive sentinel lymph nodesCompletion axillary dissectionLymph node dissectionPositive axillary nodesPositive sentinel nodesSentinel lymph nodesStandard of careInvasive surgical managementNegative axillaAxillary dissectionAxillary lymphNode dissectionAxillary nodesLymph nodesSentinel nodesSurgical managementSurgical proceduresPatientsLymphCancerDissectionTherapeutic purposes
2008
Matched Pair Analyses of Stage IV Breast Cancer with or Without Resection of Primary Breast Site
Cady B, Nathan N, Michaelson J, Golshan M, Smith B. Matched Pair Analyses of Stage IV Breast Cancer with or Without Resection of Primary Breast Site. Annals Of Surgical Oncology 2008, 15: 3384-3395. PMID: 18726129, DOI: 10.1245/s10434-008-0085-x.Peer-Reviewed Original ResearchConceptsPrimary site surgeryBreast cancer patientsMatched-pair analysisIV patientsCancer resectionBreast surgeryCancer patientsSurvival advantageStage IVSite surgeryStage IV breast cancer patientsStage IV breast cancerExcellent responseApparent survival benefitBreast cancer resectionPrimary cancer resectionStage IV patientsStage III patientsSelection biasApparent survival advantageMatched pair analysisOligo metastasisInitial chemotherapyChart reviewSurvival benefit
2004
Prediction of breast cancer size by ultrasound, mammography and core biopsy
Golshan M, Fung B, Wiley E, Wolfman J, Rademaker A, Morrow M. Prediction of breast cancer size by ultrasound, mammography and core biopsy. The Breast 2004, 13: 265-271. PMID: 15325659, DOI: 10.1016/j.breast.2004.05.005.Peer-Reviewed Original Research
2003
The effect of ipsilateral whole breast ultrasonography on the surgical management of breast carcinoma
Golshan M, Fung B, Wolfman J, Rademaker A, Morrow M. The effect of ipsilateral whole breast ultrasonography on the surgical management of breast carcinoma. The American Journal Of Surgery 2003, 186: 391-396. PMID: 14553857, DOI: 10.1016/s0002-9610(03)00280-0.Peer-Reviewed Original ResearchConceptsWhole-breast ultrasonographyBreast cancer patientsSurgical managementBreast ultrasonographyCancer patientsBreast cancerHistologic grade 2Percent of patientsBreast conservation therapyHigh-grade lesionsPrimary tumor siteFoci of carcinomaUltrasonography abnormalitiesYounger patientsConservation therapyWide resectionGrade lesionsPhysical examinationAdditional lesionsSignificant abnormalitiesBreast carcinomaPatientsGrade 2UltrasonographyTumor siteSentinel Lymph Node Biopsy Lowers the Rate of Lymphedema When Compared with Standard Axillary Lymph Node Dissection
Golshan M, Martin W, Dowlatshahi K. Sentinel Lymph Node Biopsy Lowers the Rate of Lymphedema When Compared with Standard Axillary Lymph Node Dissection. The American Surgeon 2003, 69: 209-212. PMID: 12678476, DOI: 10.1177/000313480306900306.Peer-Reviewed Original ResearchConceptsAxillary lymph node dissectionLymph node dissectionNode dissectionSentinel lymphArm circumferenceBreast cancerStandard axillary lymph node dissectionLong-term postoperative managementConventional axillary dissectionRate of lymphedemaAxillary node dissectionCent of patientsALND patientsArm edemaSLNB groupAxillary dissectionLymphedema ratePostoperative managementNonoperated sideLevel IPatientsData patientsSLNBLymphBiopsy